Best Practices, LLC Home
View Cart Search the Site Contact Best Practices, LLC Press Room of Best Practices, LLC
ABOUT US RESEARCH & CONSULTING BENCHMARKING REPORTS BEST PRACTICE DATABASE RESEARCH & ADVISORY SERVICES BEST PRACTICES EXCELLENCE SERVICES
Advanced Search
Wizards and Analytics Search
Simple Search
By Subject Area
Sales and Marketing > New Product Development and Launch > Planning and Coordinating Launch > Communication Activities
Communication Activities Research

Oncology Market Education: Engaging Key Opinion Leaders 
Non-members: Click here to review a complimentary excerpt from "Oncology Market Education: Engaging Key Opinion Leaders" STUDY OVERVIEW Educating the marketplace about a new product is part of every new product launch... (ID 5168)
Companies Profiled: GlaxoSmithKline , ARIAD, Pfizer, Integrated Communications Corp., more ...
Price: $2400.00   Free Excerpt Available
Oncology Market Education: Timing and Lessons Learned 
Non-members: Click here to review a complimentary excerpt from "Oncology Market Education: Timing and Lessons Learned" STUDY OVERVIEW Informing critical stakeholders about new therapies is an important part of any new product launch - and new oncology products are no different... (ID 5167)
Companies Profiled: GlaxoSmithKline , ARIAD, Pfizer, Integrated Communications Corp., more ...
Price: $1500.00   Free Excerpt Available
Oncology Market Education: Informing Patients and Payers 
Non-members: Click here to review a complimentary excerpt from "Oncology Market Education: Informing Patients and Payers" STUDY OVERVIEW Patient and payer support plays an important part in the success of a new oncology product entering the market... (ID 5166)
Companies Profiled: GlaxoSmithKline , ARIAD, Pfizer, Integrated Communications Corp., more ...
Price: $2400.00   Free Excerpt Available
Oncology Market Education: Communicating with the Medical Community 
Non-members: Click here to review a complimentary excerpt from "Oncology Market Education: Communicating with the Medical Community" STUDY OVERVIEW The success of an oncology product launch hinges on many things but one of the critical components is the reception in the medical community... (ID 5165)
Companies Profiled: GlaxoSmithKline , ARIAD, Pfizer, Integrated Communications Corp., more ...
Price: $1800.00   Free Excerpt Available
Payer Factors that Shape a Successful Oncology Market Entry: Education and Access Insights 
Non-members: Click here to review a complimentary excerpt from "Payer Factors that Shape a Successful Oncology Market Entry: Education and Access Insights" STUDY OVERVIEW While many factors affect a pharmaceutical new product launch, it's recognized that payers have become a critical factor in how an oncology product fares in the marketplace... (ID 5156)
Companies Profiled: GlaxoSmithKline , Bristol-Myers Squibb, Roche, Lilly, more ...
Price: $1764.00   Free Excerpt Available
Physician Factors that Shape a Successful Oncology Market Entry: Initial Trial, Thought Leader Engagement, Early Education and New Technologies 
Non-members: Click here to review a complimentary excerpt from "Physician Factors that Shape a Successful Oncology Market Entry: Initial Trial, Thought Leader Engagement, Early Education and New Technologies" STUDY OVERVIEW The pharmaceutical industry is constantly developing and launching new oncology products... (ID 5151)
Companies Profiled: GlaxoSmithKline , Bristol-Myers Squibb, Roche, Lilly, more ...
Price: $2548.00   Free Excerpt Available
Product Factors that Shape a Successful Oncology Market Entry: Differentiation, Pricing, and Therapy Benefits 
Non-members: Click here to review a complimentary excerpt from "Product Factors that Shape a Successful Oncology Market Entry: Differentiation, Pricing and Therapy Benefits" STUDY OVERVIEW New oncology products are constantly entering the biopharmaceutical marketplace; some therapies are immediate successes while others flounder for months... (ID 5150)
Companies Profiled: GlaxoSmithKline , Bristol-Myers Squibb, Roche, Lilly, more ...
Price: $2726.00   Free Excerpt Available
Best Practices in Internal Brand Communication: Timing, Technology and Success Measurement 
Non-members: Click here to review a complimentary excerpt from "Best Practices in Internal Brand Communication: Timing, Technology and Success Measurement" STUDY OVERVIEW Disease state education is an important part of a successful product launch, particularly for unknown or socially sensitive diseases... (ID 5112)
Companies Profiled: Abbott, Novartis, Actelion, Novo Nordisk, more ...
Price: $2180.00   Free Excerpt Available
Best Practices in Internal Brand Communication: Customizing Education to Raise Awareness 
Non-members: Click here to review a complimentary excerpt from "Best Practices in Internal Brand Communication: Customizing Education to Raise Awareness" STUDY OVERVIEW Disease state education is an important part of a successful product launch, particularly for unknown or socially sensitive diseases... (ID 5111)
Companies Profiled: Abbott, Novartis, Actelion, Novo Nordisk, more ...
Price: $2100.00   Free Excerpt Available
Best Practices in Internal Brand Communication: Strategies for Educating Employees 
Non-members: Click here to review a complimentary excerpt from "Best Practices in Internal Brand Communication: Strategies for Educating Employees" STUDY OVERVIEW Disease state education has long been viewed as a critical component of pre-launch communication for a new product, especially for a therapy with a new mechanism of action or in a socially sensitive therapeutic area... (ID 5110)
Companies Profiled: Abbott, Novartis, Actelion, Novo Nordisk, more ...
Price: $2100.00   Free Excerpt Available
Onglyza Case Study: Lack of Differentiation Mutes a Launch 
Non-members: Click here to review a complimentary excerpt from "Onglyza Case Study: Lack of Differentiation Mutes a Launch" STUDY OVERVIEW Onglyza, a DPP-4 inhibitor class of anti-diabetes drug, was the second DPP-4 to the market behind the blockbuster Januvia... (ID 5109)
Companies Profiled: Bristol-Myers Squibb, AstraZeneca
Price: $2760.00   Free Excerpt Available
Gardasil Case Study: Using Policy as a Springboard for Launch Success 
Non-members: Click here to review a complimentary excerpt from "Gardasil Case Study: Using Policy as a Springboard For Launch Success" STUDY OVERVIEW Gardasil is a vaccine manufactured by Merck that prevents certain diseases caused by the Human Papillomavirus (HPV), including cervical cancer and genital warts... (ID 5108)
Companies Profiled: Merck
Price: $3381.00   Free Excerpt Available
Effient Case Study: Stumbling When Taking On The Market Leader 
Non-members: Click here to review a complimentary excerpt from "Effient Case Study: Stumbling When Taking On The Market Leader" STUDY OVERVIEW The blood thinner Effient entered the market with expectations of becoming a blockbuster for Daiichi Sankyo and Eli Lilly... (ID 5107)
Companies Profiled: Eli Lilly, Daiichi Sankyo
Price: $4500.00   Free Excerpt Available
Januvia Case Study: Building a Successful Launch Around KOL, Physician, Patient and Payer Education 
Non-members: Click here to review a complimentary excerpt from "Januvia Case Study: Building a Successful Launch Around KOL, Physician, Patient and Payer Education" STUDY OVERVIEW Approved in 2006 as a treatment for Type II diabetes, Januvia is a first-in-class oral dipeptidyl peptidase-4 that was greeted enthusiastically at launch by prescribers, payers and patients... (ID 5106)
Companies Profiled: Merck
Price: $4500.00
Supporting Successful Product Launches: Tactics for Educating Payers 
Non-members: Click here to review a complimentary excerpt from "Supporting Successful Product Launches: Tactics for Educating Payers" Study Overview Effective payer education of new products has become paramount in the face of the ever-growing role of the payer and government sectors in the marketplace... (ID 5080)
Companies Profiled: GlaxoSmithKline , ARIAD, Pfizer, Integrated Communications Corp., more ...
Price: $1710.00   Free Excerpt Available
Supporting Successful Product Launches: Tactics for Educating Physicians 
Non-members: Click here to review a complimentary excerpt from "Supporting Successful Product Launches: Tactics for Educating Physicians" Study Overview Educating the marketplace about a new product is a vital prerequisite for both a therapy's launch and the critical first years on the market... (ID 5078)
Companies Profiled: GlaxoSmithKline , ARIAD, Pfizer, Integrated Communications Corp., more ...
Price: $2385.00   Free Excerpt Available
Expanding a Product Portfolio Without Cannibalizing an Established Brand 
Non-members: Click here to review a complimentary excerpt from "Expanding a Product Portfolio Without Cannibalizing an Established Brand" Study Overview Managing multiple products for the same indication is a complex balancing act for bio-pharmaceutical companies today—especially those that want to prevent one of their brands from gaining market share at the expense of another... (ID 5075)
Companies Profiled: Abbott, Alcon, Amgen, Baxter International, more ...
Price: $3900.00   Free Excerpt Available
Supporting Successful Diabetes Product Launches: Tactics for Educating Payers 
Non-members: Click here to review a complimentary excerpt from "Supporting Successful Diabetes Product Launches: Tactics for Educating Payers" Note: Data in this study are segmented to present views for Total Benchmark Class and Diabetes respondents... (ID 5073)
Companies Profiled: GlaxoSmithKline , ARIAD, Pfizer, Integrated Communications Corp., more ...
Price: $1890.00   Free Excerpt Available
Supporting Successful Diabetes Product Launches: Tactics for Educating Physicians 
Non-members: Click here to review a complimentary excerpt from "Supporting Successful Diabetes Product Launches: Tactics for Educating Physicians" Note: Data in this study are segmented to present views for Total Benchmark Class and Diabetes respondents... (ID 5072)
Companies Profiled: GlaxoSmithKline , ARIAD, Pfizer, Integrated Communications Corp., more ...
Price: $2475.00   Free Excerpt Available
Onglyza Case Study: Navigating New Safety Concerns To Win Market Approval In Diabetes 
Non-members: Click here to review a complimentary excerpt from "Onglyza Case Study: Navigating New Safety Concerns to Win Market Approval in Diabetes" STUDY OVERVIEW This case study reviews the opportunities and challenges faced by Bristol-Myers Squibb and AstraZeneca at the tail end of the development of Onglyza (saxagliptin), a treatment for type 2 diabetes... (ID 5068)
Companies Profiled: AstraZeneca, Bristol-Myers Squibb
Price: $2437.00   Free Excerpt Available
Vectibix Case Study: Collaborating with Patient Advocacy Groups to Educate the Marketplace 
Non-members: Click here to review a complimentary excerpt from "Vectibix Case Study: Collaborating with Patient Advocacy Groups to Educate the Marketplace" STUDY OVERVIEW This case study reviews how Amgen interacted with a leading patient advocacy group to support Vectibix, a colorectal cancer treatment... (ID 5067)
Companies Profiled: Amgen
Price: $1000.00   Free Excerpt Available

 


All contents copyright © 1999-2012 Best Practices, LLC 6350 Quadrangle Drive, Chapel Hill, NC 27517 USA (919) 403-0251.
Site Map | Please see our Terms and Conditions of Use and Privacy Policy.

This site is optimized for 4.0 and higher versions of Microsoft Internet Explorer and Netscape Navigator.
If you experience difficulties using our e-commerce system, please check your browser version and our FAQs.